Dynamic Purchasing System 2 0 Port Of Rotterdam N V

Deadline: 31 Mar 2028

Netherlands

Ref. No.: 25322389

EMD:Ref Document

Bid Value: Ref Document

503 Days Left

Conclusion Of Non Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V With The Active Ingredient Ustekinumab

Deadline: 10 Feb 2028

Germany

Ref. No.: 25320362

EMD:Ref Document

Bid Value: Ref Document

453 Days Left

Conclusion Of Non Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V With The Active Ingredient Tocilizumab

Deadline: 10 Feb 2028

Germany

Ref. No.: 25320331

EMD:Ref Document

Bid Value: Ref Document

453 Days Left

Conclusion Of Non Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V With The Active Ingredient Teriparatide

Deadline: 10 Nov 2027

Germany

Ref. No.: 25320290

EMD:Ref Document

Bid Value: Ref Document

361 Days Left

Conclusion Of Non Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V With The Active Ingredient Somatropin

Deadline: 10 Aug 2027

Germany

Ref. No.: 25320266

EMD:Ref Document

Bid Value: Ref Document

269 Days Left

Conclusion Of Non Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V With The Active Ingredient Ranibizumab

Deadline: 10 Feb 2027

Germany

Ref. No.: 25320246

EMD:Ref Document

Bid Value: Ref Document

88 Days Left

Conclusion Of Non Exclusive Discount Agreements In Accordance With Section 130A Paragraph 8 Sgb V With The Active Ingredient Pegfilgrastim

Deadline: 10 Feb 2028

Germany

Ref. No.: 25320219

EMD:Ref Document

Bid Value: Ref Document

453 Days Left

Conclusion Of Non Exclusive Discount Agreements In Accordance With Section 130A Paragraph 8 Sgb V With The Active Ingredient Infliximab For Subcutaneous Administration

Deadline: 10 Feb 2027

Germany

Ref. No.: 25320164

EMD:Ref Document

Bid Value: Ref Document

88 Days Left

Conclusion Of Non Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V With The Active Ingredient Golimumab

Deadline: 10 Feb 2027

Germany

Ref. No.: 25320145

EMD:Ref Document

Bid Value: Ref Document

88 Days Left

Conclusion Of Non Exclusive Discount Agreements In Accordance With Section 130A Paragraph 8 Sgb V With The Active Ingredient Follitropin Alfa

Deadline: 10 Feb 2028

Germany

Ref. No.: 25320124

EMD:Ref Document

Bid Value: Ref Document

453 Days Left

Conclusion Of Non Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V With The Active Ingredient Filgrastim

Deadline: 10 Nov 2027

Germany

Ref. No.: 25320105

EMD:Ref Document

Bid Value: Ref Document

361 Days Left

Conclusion Of Non Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V With The Active Ingredient Etanercept

Deadline: 10 Feb 2028

Germany

Ref. No.: 25320069

EMD:Ref Document

Bid Value: Ref Document

453 Days Left

Conclusion Of Non Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V With The Active Ingredient Epoetin Alfa Zeta

Deadline: 10 May 2027

Germany

Ref. No.: 25320041

EMD:Ref Document

Bid Value: Ref Document

177 Days Left

Conclusion Of Non Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V With The Active Ingredient Eculizumab

Deadline: 10 Feb 2028

Germany

Ref. No.: 25320009

EMD:Ref Document

Bid Value: Ref Document

453 Days Left

Conclusion Of Non Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V With The Active Ingredient Denosumab

Deadline: 10 May 2027

Germany

Ref. No.: 25319971

EMD:Ref Document

Bid Value: Ref Document

177 Days Left

Filter Your Search

Tenders by Countries

Browse Popular Sectors

Projects by Regions

Funding Agency

Support

CONTACT DETAILS

Filter Your Search

FREE Trial plan for all new users!